Quantcast

Industry news that matters to you.  Learn more

Quest Diagnostics’ Cleveland HeartLab Acquisition Reflects Personalized Medicine Trend

Quest Diagnostics has snapped up Cleveland Clinic spinoff Cleveland HeartLab in an equity deal and formed a strategic collaboration with the health system. The acquisition gives the national clinical lab testing business access to the HeartLab’s proprietary tests identifying biomarkers associated with cardiovascular disease that go well beyond the conventional screening tests for cholesterol.

Quest Diagnostics to Acquire Cleveland HeartLab and Form Strategic Collaboration with Cleveland Clinic

Quest Diagnostics (NYSE: DGX) today announced it has formed a definitive agreement to acquire Cleveland HeartLab, a leader in innovative diagnostic services for managing cardiovascular disease, from equity investors, including Cleveland Clinic. Quest intends to establish a national center of excellence in diagnostic information services at Cleveland HeartLab’s specialized laboratory in Cleveland, Ohio, focused on services that aid in assessing risk and treatment protocols for heart disease, the leading cause of death in the United States.

New Study Shows Cleveland HeartLab Inflammation Testing can Prevent Thousands of Heart Attacks and Strokes, Averting $187 Million in Healthcare Costs for Cardiovascular Disease

Cleveland HeartLab Inc. (CHL), the premier cardiovascular disease management company, and MDVIP, the leader in personalized, preventive medicine, are pleased to announce the publication of a seminal peer review study in the Journal of Medical Economics. The study shows that by improving cardiovascular disease risk (CVD) assessment, CHL’s inflammation testing could reduce heart attacks and strokes by nearly 10 percent.

Cleveland HeartLab Launches “it” Campaign Raises Awareness of Inflammation Testing

Cleveland HeartLab Inc. (CHL) announced today the launch of a campaign to educate patients and health care professionals about the importance of “it,” or inflammation testing, in determining heart attack and stroke risk. CHL is a specialty clinical laboratory and cardiovascular disease management company focused on offering a robust menu of propriety diagnostic tests based on unique molecular biomarkers.

BG Medicine, Inc. Announces Availability of Galectin-3 Testing Through Cleveland HeartLab, Inc.

BG Medicine, Inc., a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that Cleveland HeartLab, Inc. is now offering BGM Galectin-3 testing services.